From the smallest biotech to the biggest pharmaceutical stock The Motley Fool's Market Checkup covers the health-care sector's biggest headlines, hottest market movers, and Obamacare's ongoing rollout.
In this segment from Tuesday's episode, shares of Endo Health (NASDAQ:ENDP) soared after the company announced it is buying the Canada-based Paladin Labs for $1.5 billion. Motley Fool health-care analyst David Williamson takes a close look at the deal and tells investors why the market reacted so favorably and whether he sees this as a good time to buy.
Follow David on Twitter @MotleyDavid.
David Williamson has no position in any stocks mentioned, and neither does The Motley Fool. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.